AC Immune (ACIU) Expected to Release Earnings on Tuesday

Key Points

• AC Immune is expected to report Q3 2026 earnings before the market opens Tuesday, November 3. Analysts forecast a loss of $0.22 per share and revenue of approximately $0.33 million; the earnings call is scheduled for November 4.
• The company previously beat estimates, reporting $0.03 EPS and $18.67 million in revenue versus expectations of a $0.10 loss and $9.59 million in revenue. However, AC Immune remains unprofitable, with a negative net margin of 245.32%.
• Shares opened at $2.31 and are down 4.5%, while analyst sentiment remains a Moderate Buy with a consensus price target of $7.50, despite one recent downgrade to “sell.”

AC Immune (NASDAQ:ACIU - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.22) per share and revenue of $0.33 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 12:30 PM ET.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.13. The business had revenue of $18.67 million during the quarter, compared to analysts' expectations of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. On average, analysts expect AC Immune to post ($0.60) EPS for the current fiscal year and $0.17 EPS for the next fiscal year.

AC Immune Trading Down 4.5%

NASDAQ:ACIU opened at $2.31 on Tuesday. The company has a market cap of $235.10 million, a P/E ratio of -4.28 and a beta of 1.56. AC Immune has a twelve month low of $2.10 and a twelve month high of $4.00. The company's 50-day moving average price is $2.64 and its 200-day moving average price is $2.76.

Analyst Upgrades and Downgrades

ACIU has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating on shares of AC Immune in a research report on Thursday, September 24th. Zacks Research upgraded AC Immune from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 29th. BTIG Research reaffirmed a "buy" rating and issued a $8.00 target price on shares of AC Immune in a research note on Wednesday, September 23rd. Finally, Weiss Ratings downgraded AC Immune from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

AC Immune Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer's disease, Parkinson's disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company's technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.